生物学定义阿尔茨海默病与疾病修饰治疗时代的神经影像
疾病修饰治疗和基于生物标志物的诊断框架正在根本改变阿尔茨海默病的临床诊断与管理。诊断日益锚定于病理的生物学证据而非仅临床表现,影响治疗资格、预后和监测。脑影像尤其是MRI和PET在可视化累积异常中起关键作用,淀粉样蛋白PET在确立诊断、确定治疗资格和量化清除中居核心地位。
要点
- 诊断转向生物学证据,影响治疗资格、预后与监测。
- 淀粉样蛋白PET用于诊断、治疗资格和量化淀粉样蛋白清除。
- MRI对鉴别诊断、共病血管病理和监测并发症不可或缺。
核心结论
- 神经影像已成为阿尔茨海默病诊疗的基石和表征脑损伤的关键判别工具。
主要发现
- 诊断日益锚定于病理的生物学证据而非仅临床表现。
- 淀粉样蛋白PET在确立诊断、确定治疗资格和量化治疗相关淀粉样蛋白清除中居核心地位。
- tau PET在有条件时提供生物学分期、预后和临床异质性信息。
- MRI对鉴别诊断、评估共病和血管病理及监测并发症尤其是淀粉样蛋白相关影像异常不可或缺。
- 定量影像、人工智能、加速采集和工作流程优化正在提高可靠性、效率和可及性。
临床怎么用
- 淀粉样蛋白PET用于确立阿尔茨海默病诊断和确定淀粉样蛋白靶向治疗资格。
- tau PET在有条件时用于告知生物学分期、预后和临床异质性。
- MRI用于鉴别诊断、评估共病和血管病理以及监测并发症。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
Disease-modifying therapies and biomarker-based diagnostic frameworks will fundamentally altered the clinical diagnosis and management of Alzheimer's disease. Diagnosis is increasingly anchored in the biological evidence of pathology rather than clinical presentation alone, with implications for treatment eligibility, prognosis, and monitoring. In clinical practice, patients with memory complaints can present with complex mixed pathologies that develop across the lifespan. Brain imaging, particularly MRI and PET, plays a crucial role in visualising these cumulative abnormalities. With Alzheimer's disease-specific therapies now available in many regions of the world, amyloid PET plays a central role in establishing Alzheimer's disease diagnosis, determining eligibility for amyloid-targeting therapies, and quantifying treatment-related amyloid clearance. In settings where available, tau PET informs biological stage, prognosis, and clinical heterogeneity. MRI remains indispensable for differential diagnosis, the assessment of comorbid and vascular pathology, and monitoring for complications, particularly amyloid-related imaging abnormalities. Technological advances-including quantitative imaging, artificial intelligence, accelerated acquisition, and workflow optimisation-are improving reliability, efficiency, and access to these tools. Neuroimaging is now a cornerstone of Alzheimer's disease care and a crucial discriminator tool for characterising brain injury across the lifespan. With emerging fluid biomarkers, neuroimaging supports accurate diagnosis, prognosis, and treatment monitoring.
引用
- Benzinger TLS, Cogswell PM, Arani A, et al. Neuroimaging in the era of biologically defined Alzheimer's disease and disease-modifying therapy. Lancet Neurol. 2026. PMID: 42716046. doi:10.1016/S1474-4422(26)00285-1
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。